Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Anastrazole|DRUG: Gefitinib
Sponsor: AstraZeneca